modelG03XB01

Diagram of G03XB01

Extends from Pharmacokinetic.Models.PK_2C_enteral.

Information

name:Mifepristone
ATC code:G03XB01
route:oral
compartments:2
dosage:200mg
volume of distribution:120L
clearance:4.5L/h
other parameters in model implementation

Mifepristone is a synthetic steroid compound that acts as a progesterone receptor antagonist. It is primarily used as an abortifacient in combination with misoprostol for the medical termination of intrauterine pregnancy. It is also approved for the management of hyperglycemia in Cushing's syndrome and investigated for other indications. Mifepristone is FDA-approved and widely used in clinical practice.

Pharmacokinetics

Population oral pharmacokinetic parameters in healthy adult females after a 200 mg dose in clinical studies.

References

  1. Teng, YN, et al., & Guo, RC (2011). Determinations of mifepristone and its metabolites and their pharmacokinetics in healthy female Chinese subjects. Yao xue xue bao = Acta pharmaceutica Sinica 46(10) 1241–1245. PUBMED:https://pubmed.ncbi.nlm.nih.gov/22242458

  2. He, CH, et al., & Fotherby, K (1989). Pharmacokinetic study of orally administered RU 486 in non-pregnant women. Contraception 40(4) 449–460. DOI:10.1016/0010-7824(89)90052-8 PUBMED:https://pubmed.ncbi.nlm.nih.gov/2582770

  3. Spitz, IM, et al., & Wade, CE (1993). The divergent effect of RU 486 on adrenal function in the dog is related to differences in its pharmacokinetics. Acta endocrinologica 128(5) 459–465. DOI:10.1530/acta.0.1280459 PUBMED:https://pubmed.ncbi.nlm.nih.gov/8391196

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.VolumeVdp (from PK_2C)VdpPerKg*weightVolume of distribution (m3)
Modelica.Units.SI.SpecificVolumeVdpPerKg (from PK_2C)0.9Volume of distribution peripheral(l/kg)
Pharmacolibrary.Types.Clearancek12 (from PK_2C)1intercompartmental C-P clearance
Pharmacolibrary.Types.Clearancek21 (from PK_2C)1intercompartmental P-C clearance
Pharmacolibrary.Types.TransferRateka (from PK_2C_enteral)0.016666666666666666first order absorption rate
Modelica.Units.SI.TimeTlag (from PK_2C_enteral)600delay between oral administration and absorption (default 10min)

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)
Interfaces.ConcentrationPort_bperipheralCPort (from PK_2C)
Pharmacolibrary.Types.ConcentrationOutputC_peripheral1 (from PK_2C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life
Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSymtransfer (from PK_2C)
Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartmentperipheral (from PK_2C)

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)